Please login to the form below

Not currently logged in
Email:
Password:

Arresto Biosciences

This page shows the latest Arresto Biosciences news and features for those working in and with pharma, biotech and healthcare.

Gilead chalks up trial success for new NASH drug

Gilead chalks up trial success for new NASH drug

The phase II trial is looking at selonsertib (GS-4997) on its own or in combination with Gilead's other NASH candidate simtuzumab - acquired along with Arresto Biosciences for $225m in

Latest news

  • Gilead's simtuzumab fails pancreatic cancer trial Gilead's simtuzumab fails pancreatic cancer trial

    Simtuzumab - which was acquired by Gilead when it bought Arresto Biosciences for $225m in 2010 - is also in phase II trials for idiopathic pulmonary fibrosis, myelofibrosis, non-alcoholic steatohepatitis (NASH) and

  • Gilead to acquire Calistoga

    The Calistoga acquisition comes on the heels of the company's acquisitions last year of two other small biotech companies, CGI Pharmaceuticals and Arresto Biosciences, both of which are also developing ... Gilead acquired Arresto for $225m plus potential

  • Gilead to acquire Arresto Bioscences

    Gilead will acquire Arresto Biosciences for $225m plus potential future payments based on sales levels. ... Arresto Viosciences is a privately held development-stage technology company focused on medicines to treat fibrotic diseases and cancer.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics